vigencell ema

Search results

Advanced search

Scope

Title Contents All

Date

Bio & Pharma
ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment

ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...

Oct 25, 2024 (Gmt+09:00)

language
Energy
LS Eco Energy to supply UHV cables to Singapore's EMA

South Korea's LS Eco Energy Ltd. announced on Tuesday that its Vietnamese production subsidiary, LS-VINA, will supply 12 billion won ($8.99 million)...

Mar 05, 2024 (Gmt+09:00)

language
Bio & Pharma
ViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe

ViGenCell, a company specializing in immune cell therapy, announced on the 19th that its NK/T cell lymphoma treatment "VT-EBV-N" has been designated...

Dec 27, 2023 (Gmt+09:00)

language
Bio & Pharma
Celltrion applies for approval in Europe for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...

Nov 24, 2023 (Gmt+09:00)

language
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...

Jan 16, 2023 (Gmt+09:00)

language

Stay Korea Savvy
with our newsletters

Fill in the information to subscribe to our newsletter and you can also getunlimited access to the latest intelligence on Korean asset owners.